(PLoS Medicine[TA])
5,342 results
  • Self-explaining artificial intelligence for the classification of B cell non-Hodgkin lymphoma: A diagnostic decision support study. [Journal Article]
    PLoS Med. 2026 Jul 13; 23(7):e1004889. [Online ahead of print]Thrun MC, Hoffmann J, … Ultsch APM
  • CONCLUSIONS: FlowXAI provides accurate, data-efficient, and transparent support for B-NHL immunophenotyping from nonstandardized flow cytometry data. By combining interpretable decision logic with explicit self-assessment, FlowXAI offers a clinically meaningful framework for diagnostic support and training, particularly in settings with limited expert availability or rare lymphoma subtypes. The main limitation is the retrospective evaluation using specific antibody panels, and FlowXAI requires prospective validation as a decision-support tool within integrated diagnostic workflows.
  • How to benchmark medical AI agents. [Journal Article]
    PLoS Med. 2026 Jul; 23(7):e1005170.Ruhrberg Estévez S, Ferber D, … Kather JNPM
  • Medical artificial intelligence research is shifting from single-task models toward multimodal large language model-based agents for complex clinical workflows, requiring benchmarks that assess clinical reasoning, process safety, and resource stewardship rather than final outputs alone.
  • Discordance in orphan drug approvals between the U.S. Food and Drug Administration and the European Medicines Agency: A retrospective observational analysis. [Journal Article]
    PLoS Med. 2026 Jul 06; 23(7):e1004861. [Online ahead of print]Ding J, Hopkins MM, Martin PAPM
  • CONCLUSIONS: Between 2011 and 2023, regulatory outcomes for orphan drug approvals increasingly diverged between the FDA and the EMA, particularly for cancer indications and approvals sponsored by small US sponsors. Among FDA orphan drugs authorised by the EMA, many were not designated as orphan products because of regulatory differences, particularly regarding requirements around significant benefit and biomarker-defined sub-populations in oncology. FDA-approved orphan drugs that lack EU marketing authorisation may be withheld by companies not because of regulatory barriers but due to insufficient commercial incentives to launch in Europe, resulting in fewer treatment options for European rare disease patients. Our findings suggest that orphan incentives are not the primary driver of commercial EU-launch decisions and that recent EU regulatory reform of these incentives may not achieve their goal of improving access to therapy for rare diseases.
  • Precision oncology's translation gap-Can molecular tumor boards bridge it? [Journal Article]
    PLoS Med. 2026 Jun; 23(6):e1005165.Byrne MM, Kolesar JMPM
  • Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?
  • Improving suicide prevention in men. [Editorial]
    PLoS Med. 2026 Jun; 23(6):e1005169.Fazel SPM
  • Despite public health strategies focusing on men's mental health and suicide risk, rates of suicide among men remain concerningly high. Targeted, specialized approaches for high-risk individuals should be prioritized alongside broader population-level strategies.
  • Association of armed conflict and global measles cases: A structural equation modeling analysis of 193 countries from 2000 to 2023. [Journal Article]
    PLoS Med. 2026 Jun; 23(6):e1004819.Headley TY, Tozan YPM
  • CONCLUSIONS: Armed conflict is associated with an increased measles burden, both directly and indirectly through associations with lower socioeconomic development and greater population displacement. These findings suggest that mitigating infectious disease risks in volatile settings requires a dual strategy: preserving the structural foundations of health and education while systematically integrating displaced populations into routine immunization programs. Future research using subnational and higher-frequency data is needed to clarify the precise mechanisms and timing of these associations across other vaccine-preventable diseases.